Leadless Versus Transvenous Single‐Chamber Ventricular Pacemakers: Real‐World Evidence From Aveir VR Coverage With Evidence Development Study
Journal of the American Heart Association · 04.11.2025 · 14 (21)
DOI: 10.1161/jaha.125.042471 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, erschienen am 04.11.2025. Verfasst von James E Ip und 9 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine New York Presbyterian Hospital Division of Cardiology New York NY. Hauptthemen laut MEDLINE: Pacemaker, Artificial, Arrhythmias, Cardiac, Cardiac Pacing, Artificial. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Aveir VR, a helix‐fixation leadless pacemaker (LP), was US Food and Drug Administration (FDA)‐approved in 2022. The performance of this novel LP has not been evaluated against transvenous single chamber ventricular pacemakers (TV‐VVI) in a real‐world setting. This observational coverage with evidence development study of Aveir VR implants (Aveir coverage with evidence development) evaluates complications and outcomes among Medicare beneficiaries implanted with Aveir VR immediately after FDA approval compared with those implanted with TV‐VVI.
Methods
Medicare fee‐for‐service and Abbott device registration data were used to identify de novo Aveir VR LP (implanted 6/2022–6/2024) or TV‐VVI (all manufacturers, implanted 1/2021–6/2024). Outcomes evaluated included 30‐day and 12‐month complications, reinterventions, and mortality rates, adjusted for demographics, comorbidities, and hospital encounter characteristics.
Results
Among 2425 Aveir VR LP and 21 335 TV‐VVI patients included in this analysis, Aveir VR patients had significantly fewer acute device‐related complications (1.4% versus 2.8%, P =0.002). Overall acute complications were similar between Aveir VR (6.5%) and TV‐VVI (6.8%), P =0.69. Cardiac effusion/perforation rates were also similar between Aveir VR (0.4%) and TV‐VVI (0.3%), P =0.45. Aveir VR had a 30% lower overall 12‐month complication rate compared with TV‐VVI (4.1% versus 5.7%, P =0.02), including a 47% lower device‐related complication rate (2.8% versus 5.2%, P =0.0002). There were 61% fewer 12‐month reinterventions with Aveir VR compared with TV‐VVI (1.2% versus 3.2%, P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Weill Cornell Medicine New York Presbyterian Hospital Division of Cardiology New York NY.
- Advocate Health Chicago IL.
- Medical University of South Carolina Charleston SC.
- Montreal Heart Institute Université de Montréal Montreal Quebec Canada.
- Abbott Sylmar CA.
- Abbott Santa Clara CA.
ORCID-Profile: James E Ip, Peter A Brady, Anne M Kroman, Blandine Mondésert, Deepti Bettampadi, Rahul N Doshi
Zitieren
APA
Ip, J. E., Brady, P. A., Kroman, A. M., Mondésert, B., Ganz, L., Joseph, J. M., Bettampadi, D., Hu, Y., Nabutovsky, Y., & Doshi, R. N. (2025). Leadless Versus Transvenous Single‐Chamber Ventricular Pacemakers: Real‐World Evidence From Aveir VR Coverage With Evidence Development Study. Journal of the American Heart Association, 14(21). https://doi.org/10.1161/jaha.125.042471
Vancouver
Ip JE, Brady PA, Kroman AM, Mondésert B, Ganz L, Joseph JM, et al. Leadless Versus Transvenous Single‐Chamber Ventricular Pacemakers: Real‐World Evidence From Aveir VR Coverage With Evidence Development Study. Journal of the American Heart Association. 2025;14(21). doi:10.1161/jaha.125.042471
BibTeX
@article{Ip2025,
author = {Ip, James E and Brady, Peter A and Kroman, Anne M and Mondésert, Blandine and Ganz, Leonard and Joseph, Jennifer M and Bettampadi, Deepti and Hu, Yajing and Nabutovsky, Yelena and Doshi, Rahul N},
title = {Leadless Versus Transvenous Single‐Chamber Ventricular Pacemakers: Real‐World Evidence From Aveir VR Coverage With Evidence Development Study},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {21},
doi = {10.1161/jaha.125.042471}
}
EUVIMED